{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:02:12Z","timestamp":1719187332436},"reference-count":50,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2010,9,30]]},"DOI":"10.2217\/fon.10.105","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T16:18:17Z","timestamp":1286209097000},"page":"1479-1484","source":"Crossref","is-referenced-by-count":9,"title":["The Potential of Immunomodulatory Drugs in the Treatment of Solid Tumors"],"prefix":"10.1080","volume":"6","author":[{"given":"Angus","family":"Dalgleish","sequence":"first","affiliation":[{"name":"St George\u2019s University of London, Cranmer Terrace, LondonSW17 0RE, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Galustian","sequence":"additional","affiliation":[{"name":"St George\u2019s University of London, Cranmer Terrace, LondonSW17 0RE, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,10,4]]},"reference":[{"key":"e_1_3_2_3_1_1","doi-asserted-by":"publisher","DOI":"10.2174\/157489207780832478"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.01.022"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1323"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015909"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196238"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_3_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560802627903"},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.12.004"},{"key":"e_1_3_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061292"},{"key":"e_1_3_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3282f0e12b"},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.06063"},{"key":"e_1_3_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-175778"},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"e_1_3_2_3_15_1","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.","volume":"118","author":"Ramsay AG","year":"2008","unstructured":"Ramsay AG , JohnsonAJ, LeeAMet al.: Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.J. Clin. Invest.118, 2427\u20132437 (2008).","journal-title":"J. Clin. Invest."},{"key":"e_1_3_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.3116.3116"},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902756586"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-133108"},{"key":"e_1_3_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07548.x"},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-229039"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601579"},{"key":"e_1_3_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.10.4914"},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.8504"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9228-6"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4"},{"key":"e_1_3_2_3_28_1","unstructured":"Henry JY LuL AdamsMet al.: Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo . Presented at: 101st Annual Meeting of the American Association for Cancer Research . Washington DC USA 17\u201321 April 2010."},{"key":"e_1_3_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4524"},{"key":"e_1_3_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1237-9"},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"crossref","first-page":"Abstr","DOI":"10.1200\/jco.2009.27.15_suppl.5156","article-title":"A Phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer.","volume":"27","author":"Petrylak DP","year":"2009","unstructured":"Petrylak DP , Resto-GarcesK, TibyanM, MohileSG: A Phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer.J. Clin. Oncol.27(Suppl.), Abstr. 5156 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_32_1","unstructured":"Nabhan C TolzienK KelbyK LestingiTM: Lenalidomide (Revlimid \u00ae ) has single agent activity in chemotherapy-na\u00efve castration-resistant prostate cancer (CRPC). Presented at: 2010 Genitourinary Cancers Symposium . San Francisco CA USA 5\u20137 March 2010."},{"key":"e_1_3_2_3_33_1","doi-asserted-by":"crossref","first-page":"Abstr","DOI":"10.1200\/jco.2009.27.15_suppl.5130","article-title":"A randomized double blind Phase I\u2013II study to determine the tolerability\/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT).","volume":"27","author":"Sinibaldi VJ","year":"2009","unstructured":"Sinibaldi VJ , CarducciMA, Moore-CooperSet al.: A randomized double blind Phase I\u2013II study to determine the tolerability\/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT).J. Clin. Oncol.27(Suppl.), Abstr. 5130 (2009).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_3_34_1","doi-asserted-by":"crossref","unstructured":"Brosseau C ColstonK DalgleishAG GalustianC: The immunomodulatory drug lenalidomide restores a vitamin D sensitive phenotype to the vitamin D resistant breast cancer cell line MDA-MB-231.Presented at:101st Annual Meeting of the American Association for Cancer ResearchWashington DC USA 17\u201321 April 2010.","DOI":"10.1158\/1538-7445.AM10-5418"},{"key":"e_1_3_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605465"},{"key":"e_1_3_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1562"},{"key":"e_1_3_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-26283-0_1"},{"key":"e_1_3_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01954.x"},{"key":"e_1_3_2_3_39_1","first-page":"1864","article-title":"Lenalidomide augments immune responses to prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines.","volume":"114","author":"Noonan KA","year":"2009","unstructured":"Noonan KA , FergusonA, EmerlingAet al.: Lenalidomide augments immune responses to prevnar vaccination in relapsed myeloma patients: implications for cancer and infectious vaccines.ASH Annual Meeting Abstracts114, 1864 (2009).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.052"},{"key":"e_1_3_2_3_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000210620.75707.ac"},{"key":"e_1_3_2_3_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2007.0194"},{"key":"e_1_3_2_3_43_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.8-3-267"},{"key":"e_1_3_2_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70205-6"},{"key":"e_1_3_2_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)00409-0"},{"key":"e_1_3_2_3_46_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008307821189"},{"key":"e_1_3_2_3_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(99)90155-5"},{"key":"e_1_3_2_3_48_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1401"},{"key":"e_1_3_2_3_49_1","doi-asserted-by":"publisher","DOI":"10.1053\/clon.2001.0030"},{"key":"e_1_3_2_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11141-X"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.10.105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:30Z","timestamp":1719124950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.10.105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,30]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9,30]]}},"alternative-id":["10.2217\/fon.10.105"],"URL":"https:\/\/doi.org\/10.2217\/fon.10.105","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,30]]}}}